HempNewsBreaks

ThursdayAug 15, 2024 11:39 am

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports on Voting Results of 2024 Annual and Special Meeting of Shareholders

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, is reporting on its 2024 Annual and Special Meeting of Shareholders. The meeting. According to the announcement, shareholders voted on and approved all five proposals on the agenda. Proposals included the election of four directors to the company’s board of directors; the reappointment of Davidson & Company LLP, an independent registered public accounting firm, as the company auditors; amending FLGC’s Incentive Compensation Plan to increase the issuable number of shares; granting stock appreciation rights to the company's CEO and CFO; and issuing 635,363 shares in accordance with NASDAQ guidelines…

Continue Reading

TuesdayAug 06, 2024 1:35 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting recent results from its WEIGHT-A24-1 animal study. A recent article notes that interim results, which are based on the first 28 days of dosing, are “noteworthy,” including all animals showing either a noticeable decrease in the rate of body weight gain or the beginning of weight reduction. According to the article, the study was designed to the impact of Lexaria’s patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss; the article noted that this study marks a “significant milestone”…

Continue Reading

TuesdayJul 30, 2024 11:44 am

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and…

Continue Reading

ThursdayJul 25, 2024 1:04 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Significant Advancements Following Cargo Management Group Acquisition

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today provided key updates following its acquisition of Cargo Management Group (“CMG”). The acquisition was completed in June and has been instrumental in developing GTVH’s four-pillar model and setting the stage for future growth within the organization. According to the company, the formation of LE Logistic LLC, a wholly owned subsidiary of GTVH, marked a major milestone in its journey towards future growth. This entity is expected to take full charge of the company’s logistics operations once the motor carrier (“MC”) authority from CMG is fully transferred and can be integrated.…

Continue Reading

TuesdayJul 16, 2024 1:31 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects and initiatives. With that in mind, the company has named Nelson Cabatuan as consulting chief strategic financial advisor; Cabatuan is currently serving as Lexaria CFO. In his new role, Cabatuan will leverage his skills in corporate finance and strategic industry relationships to focus on strategic opportunities. In addition, Lexaria is working on other research and development projects…

Continue Reading

TuesdayJul 09, 2024 3:20 pm

HempNewsBreaks – CannaCon Event to Propel Networking, Knowledge Exchange in Fast-Growing Sector

CannaCon, a premier conference company that produces state-of-the-art B2B events for cannabis businesses, marijuana entrepreneurs, investors, and community partners to showcase industry products, people, innovations, and technology, today announced plans to host the 5th CannaCon Midwest St.Paul on Aug. 16-17, 2024. The event, designed to drive growth of the cannabis industry in both the Midwest and nationally while creating lasting value for the sector through high-powered networking and knowledge exchange, is slated to take place at the iconic Saint Paul River Center in St. Paul, Minnesota. Like-minded entrepreneurs and industry professionals will convene for the event with a mission to…

Continue Reading

TuesdayJul 09, 2024 2:28 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study arm used a Rybelsus(R) composition processed with DehydraTECH that is compliant with the FDA’s Inactive Ingredient Database (“FDA IID”), delivered within an in-mouth dissolvable tablet. According to the announcement, this will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can absorb at any level systemically through the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective drug delivery into…

Continue Reading

MondayJul 08, 2024 3:50 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. Following an earlier one granted in Canada, this is the company’s second patent in this family. In Canada, Lexaria has received a new patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the company’s fourth granted patent in this family, which was previously granted in the U.S., Australia and Japan. Further, building…

Continue Reading

MondayJul 01, 2024 3:35 pm

HempNewsBreaks – Golden Triangle Ventures Inc.’s (GTVH) Lavish Moves to Become Staple in the Entertainment Industry

Golden Triangle Ventures’ (OTC: GTVH) Lavish Entertainment embodies GTVH’s focus on vertical integration to cut costs and maximize margins, as evidenced by its recently released four-pillar business model. “According to GTVH, this strategic framework provides an essential piece of Lavish’s mission to create an industry leading entertainment business. The company’s new model includes key foundational elements – logistics, staffing, equipment and production – that were carefully identified and organized to complement each other and ensure seamless operations across all facets of the company. With its new business model as a backdrop, Lavish Entertainment plans to develop and acquire operations in…

Continue Reading

ThursdayJun 27, 2024 3:30 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes… The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and…

Continue Reading